Company intelligence / Profile preview

Flagship Pioneering

Cambridge, Massachusetts, United Statesx.com ↗

Ownership: Private
Employees: ~655
Development stage: Other

Overview

Flagship Pioneering does not develop drugs directly but founds and builds biotech platform companies. Its ecosystem has produced over 100 ventures with more than $75 billion in aggregate value. Notable successes include Moderna’s COVID‑19 vaccine. The breadth of clinical results spans from early-stage research to approved therapies across diverse therapeutic areas via its portfolio firms

Therapeutic areas: OncologyImmunologyRare DiseasesInfectious Diseases
Modalities: mRNA-based drugsSmall moleculeMonoclonal antibodyGene therapyCell therapyCRISPR-based therapy
Industry: Investors

Partnerships

PfizerGenentechThermo Fisher ScientificNovo NordiskSamsungGSK

Beyond the preview

Go deeper on Flagship Pioneering.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flagship Pioneering.

Explore the full profile